FibroBiologics, Inc. filings document the regulatory record of a clinical-stage biotechnology issuer developing fibroblast-based therapies. Recent disclosures cover registered equity financing through an at-the-market common stock program, shelf registration mechanics, common stock and warrant-related capital structure matters, and corporate uses of proceeds for working capital and general corporate purposes.
The company’s SEC filings also record governance and public-company administration, including annual meeting proxy proposals, director election and auditor ratification matters, stock-plan option grants to executive officers, Nasdaq continued-listing compliance, amendments to stockholder-meeting quorum provisions, and material agreements affecting its operating footprint.
FibroBiologics, Inc. has updated its existing at-the-market stock offering program with H.C. Wainwright & Co. Under a new prospectus supplement filed on May 5, 2026, the company may sell shares of common stock for an aggregate offering price of up to $7,500,000 under this ATM facility.
The ATM sales are made pursuant to FibroBiologics’ shelf registration statement on Form S-3, declared effective by the SEC on February 10, 2025, and related prospectus supplements. To date, 71,830 shares have been sold under the Sales Agreement. The company also filed its counsel’s legal opinion and consent covering the validity of the shares issuable under the program.
FibroBiologics filed a prospectus supplement updating its at‑the‑market sales capacity under the Form S-3 registration: it may sell up to $7,500,000 of Common Stock from time to time through H.C. Wainwright & Co. The supplement states the company sold approximately $8.14 million of Common Stock in the prior 12 months and sold about $0.17 million under the earlier supplement. The company reports a public float of approximately $47.0 million based on 5,399,112 shares held by non‑affiliates as of May 5, 2026, and notes Nasdaq closing prices of $1.38 (May 4, 2026) and $8.70 (March 6, 2026) used in float calculation. The offering is subject to the Form S-3 General Instruction I.B.6 limitations and the Sales Agreement, with any additional sales requiring a new prospectus supplement.
FibroBiologics, Inc. reported new stock option grants to its senior leadership under the company’s 2022 Stock Plan. On May 4, 2026, the Compensation Committee granted options to purchase 92,410 shares of common stock to Chief Executive Officer Pete O’Heeron at an exercise price of $1.38 per share.
Each of Chief Financial Officer Jason D. Davis, Chief Scientific Officer Hamid Khoja, Ph.D., and General Counsel Ruben A. Garcia received options to purchase 61,607 shares, also at $1.38 per share. One quarter of each grant vests on the first anniversary of the grant date, with the remaining options vesting in 36 equal monthly installments for executives who remain in continuous service.
FibroBiologics, Inc. is asking stockholders to vote at its June 22, 2026 virtual annual meeting on director elections, auditor ratification, a significant warrant-related share issuance and a new equity incentive plan.
Proposal 3 seeks approval, for Nasdaq Listing Rule 5635(d) purposes, for up to 2,272,728 shares of common stock from March 2026 investor warrants and up to 159,091 shares from placement agent warrants, both tied to a prior financing. Proposal 4 would adopt the 2026 Equity and Incentive Compensation Plan with 2,000,000 new shares plus 339,199 remaining from the 2022 plan and an annual “evergreen” increase of up to 4% of shares outstanding through 2036, which could raise fully diluted overhang from 10.7% to 33.5%.
The company also outlines voting mechanics, including 5,208,915 common shares (one vote each) and 125 shares of Series C Preferred Stock with 13,000 votes per share, and the Board’s plan to cast 1,625,000 votes (about 24% of total voting power) in favor of all proposals under an irrevocable proxy.
FibroBiologics, Inc. reported that its Chief Executive Officer, O'HEERON PETE, received a grant of stock options. The award covers 92,410 options to buy common stock at an exercise price of $1.38 per share, expiring on May 4, 2036.
According to the vesting schedule, one quarter of the option shares will vest on the one-year anniversary of the May 4, 2026 grant date. The remaining shares will vest in 36 equal monthly installments, provided the CEO remains in continuous service. Following this grant, the filing shows 92,410 derivative securities held directly.
FibroBiologics, Inc. reported that its Chief Executive Officer, O'HEERON PETE, received a grant of stock options. The award covers 92,410 options to buy common stock at an exercise price of $1.38 per share, expiring on May 4, 2036.
According to the vesting schedule, one quarter of the option shares will vest on the one-year anniversary of the May 4, 2026 grant date. The remaining shares will vest in 36 equal monthly installments, provided the CEO remains in continuous service. Following this grant, the filing shows 92,410 derivative securities held directly.
FibroBiologics, Inc. reported that Chief Scientific Officer Hamid Khoja received a stock option grant covering 61,607 shares of common stock at an exercise price of $1.38 per share. All 61,607 options are held directly and vest over four years, with one quarter vesting after one year and the remainder vesting monthly thereafter, contingent on continuous service.
FibroBiologics, Inc. reported that Chief Scientific Officer Hamid Khoja received a stock option grant covering 61,607 shares of common stock at an exercise price of $1.38 per share. All 61,607 options are held directly and vest over four years, with one quarter vesting after one year and the remainder vesting monthly thereafter, contingent on continuous service.
FibroBiologics, Inc. reported that Chief Financial Officer Jason Davis received a grant of stock options covering 61,607 shares of common stock at an exercise price of $1.38 per share. The options expire on May 4, 2036 and represent a compensation award, not an open-market trade.
According to the vesting terms, one quarter of the option shares will vest on the one-year anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments as long as Davis remains in continuous service. Following this grant, he holds 61,607 stock options directly.
FibroBiologics, Inc. reported that Chief Financial Officer Jason Davis received a grant of stock options covering 61,607 shares of common stock at an exercise price of $1.38 per share. The options expire on May 4, 2036 and represent a compensation award, not an open-market trade.
According to the vesting terms, one quarter of the option shares will vest on the one-year anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments as long as Davis remains in continuous service. Following this grant, he holds 61,607 stock options directly.
FibroBiologics, Inc. reported a routine equity compensation move for its General Counsel, Ruben A. Garcia. On May 4, 2026, he was granted a stock option covering 61,607 shares of common stock at an exercise price of $1.38 per share, expiring on May 4, 2036.
According to the filing, one quarter of the option will vest on the one-year anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments, assuming he remains in continuous service. Following this grant, his reported derivative holdings consist of options for 61,607 underlying shares.
FibroBiologics, Inc. reported a routine equity compensation move for its General Counsel, Ruben A. Garcia. On May 4, 2026, he was granted a stock option covering 61,607 shares of common stock at an exercise price of $1.38 per share, expiring on May 4, 2036.
According to the filing, one quarter of the option will vest on the one-year anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments, assuming he remains in continuous service. Following this grant, his reported derivative holdings consist of options for 61,607 underlying shares.
FibroBiologics is offering up to $6,150,000 of its common stock in an at‑the‑market offering under a Sales Agreement with H.C. Wainwright & Co., allowing sales from time to time on Nasdaq at prevailing market prices. The company completed a 1-for-20 reverse stock split effective March 30, 2026, and reported 5,208,915 shares outstanding prior to this offering. The Sales Agreement pays a 3.0% sales commission to Wainwright; net proceeds, timing and the number of shares sold will vary with market prices. The prospectus notes the company’s public float calculation and Nasdaq listing compliance steps and discloses that the April registered offering generated approximately $2.5M in net proceeds.